Paul Meadows on helping found IFESS and Imthera neurostimulation
Neural Implant podcast - the people behind Brain-Machine Interface revolutions
Release Date: 09/05/2023
Mounya Elhilali on her auditory processing selectivity research
Neural Implant podcast - the people behind Brain-Machine Interface revolutions
did the keynote talk at the . I was able to sit down with her and talk to learn more about her auditory processing selectivity research. Top 3 Takeaways: Nurses especially can get used to beeping and alarms which can be dangerous for patients. "Under anesthesia, you see some basic responses, but they are different than when you engage the, let's say, an animal in an awake state, and then when they are awake and actually behaving and engaging with the system" Audio recordings can be tuned to remove ambient noise but they need to be perfectly calibrated to distances between microphones. ...
info_outline
Suraj Mudichintala on investing in bioelectronic medicine companies with Action Potential Venture
Neural Implant podcast - the people behind Brain-Machine Interface revolutions
Suraj Mudichintala is a Senior Associate at Action Potential Capital which is GSK's bioelectronic medicine venture fund. Top 3 Takeaways: "Our fund is different in that we invest actually directly off of GSK's balance sheet. So we're what's called an evergreen fund where we don't actually have a fund size" "The way that I think about it is that a VC is really paid to allocate capital but really is really paid to think. You really have to think about what is the next space or the next technology that could disrupt a space? And because of that, it's a much you often have to take a much more...
info_outline
Balint Varkuti on turning neuromodulation technologies into Brain-Computer-Interfaces using software by CereGate
Neural Implant podcast - the people behind Brain-Machine Interface revolutions
Balint Varkuti is the CEO of CereGate which unlocks new capabilities for existing neuromodulation technologies using software. Top 3 Takeaways: "the brain is naturally wired for pattern perception for learning, and that's really what we do. We send signals that the brain very quickly can pick up." "You do not need to exclusively be focused mentally, consciously on interpreting these signals. Rather it becomes second nature. Our favourite analogy is saying it is like braille for the brain." "With hardware, you sometimes have simply the disadvantage that you are married to the time point when...
info_outline
Kevin Tracey returns to the podcast to give an update about his work at the Feinstein Institutes, the field of bioelectronic medicine and exciting vagus nerve clinical trials underway
Neural Implant podcast - the people behind Brain-Machine Interface revolutions
returns to the podcast to give an update about his work at the and the work at . Top 3 Takeaways: "Two years we discovered that a drug called Famotidine, which is sold as a generic drug Pepcid AC is actually a pharmacological or a drug-based vagus nerve stimulator. And we proved first in mice that famotidine placed directly in very small amounts placed directly in the brains of mice activates the vagus nerve. And this in turn turned off cytokine storm, which of course is a big problem in Covid 19" "A company that I've co-founded, Setpoint Medical, is currently deep into clinical trials in...
info_outline
Israel Gasperin on measuring cannabis effects quanitatively with EEG with Zentrela
Neural Implant podcast - the people behind Brain-Machine Interface revolutions
is the founder and CEO of which uses wearable EEG caps to quantitatively measure cannabis experiences. Top 3 Takeaways: "The reason why the government funded us was to use this for safety and law enforcement" "The combination of features that AI is finding is something that we haven't really focused on studying and trying to understand. It's a black box today that, is accurately and objectively characterizing the psychoactive effects, but we don't exactly know what they mean." "Based on this neuroscience-driven research proving the onset time of the beverage, within two weeks [the...
info_outline
Colin Kealey on the non-pharmaceutical adolescent ADHD treatment with NeuroSIgma
Neural Implant podcast - the people behind Brain-Machine Interface revolutions
is the President and CEO of which is commercializing the Monarch eTNS System, the first non-drug treatment for pediatric ADHD cleared by the FDA. Top 3 Takeaways: NeuroSigma is commercializing the Monarch eTNS system, a wearable medical device that stimulates the trigeminal nerve on the forehead, as a treatment for neurologic and neuropsychiatric indications. The Monarch eTNS System is FDA cleared as a treatment for pediatric ADHD, ages 7 – 12. Clinical trials in this population show a response rate of 50% with a only mild side effects observed in clinical trials to date. NeuroSigma...
info_outline
Craig Mermel on working at Google and Apple and now at Precision Neuroscience
Neural Implant podcast - the people behind Brain-Machine Interface revolutions
is the President and Chief Product Officer at which is a company looking to commercialize Brain-Computer Interfaces using a minimally implantation method and a soft electrode device. ***This podcast is sponsored by Iris Biomedical, check out their Neurotech Startup Services Top 3 Takeaways "The combination of both the nature of our thin film and the surgical innovations that we bring enables us to bring cortical surface neurotechnology to patients in a minimally invasive fashion." "Having 10 times the amount of money at an early stage before you actually solve some of the key problems can...
info_outline
Lothar Krinke on adaptive Deep Brain Stimulation at Newronika
Neural Implant podcast - the people behind Brain-Machine Interface revolutions
Lothar Krinke is the CEO and Board Member of Newronika which is an adaptive Deep Brain Stimulator company looking to improve patient outcomes in things like Parkinson's and Essential Tremor. ***This podcast is sponsored by Iris Biomedical, check out their Neurotech Startup Services Top 3 Takeaways: "the one thing we do need to address is really the cost. The cost driver of Deep Brain Stimulation isn't the manufacturing of the system. Now, that's not cheap either it's certainly less than $10,000. How expensive is brain surgery, particularly functional brain surgery? How expensive is it to...
info_outline
Damiano G. Barone on being a neurosurgeon and improving patient quality of life through surgery
Neural Implant podcast - the people behind Brain-Machine Interface revolutions
is a neurosurgery clinical lecturer at the University of Cambridge and fellow at The Walton Centre in Liverpool, UK. He is interested in tackling basic and translational challenges for the development of the next generation of neural bioelectronics. ***This podcast is sponsored by Ripple Neuro, check out their Neuroscience Research Tools Top 3 Takeaways: "My favorite procedure is the procedure that works and you see the patient after that is is a changed patient." "You come out from medical school like age 23 or 24. Then you get to a general medical program which in the...
info_outline
Jon Sakai on interacting with your target patients and the neural sleeve made by Cionic
Neural Implant podcast - the people behind Brain-Machine Interface revolutions
is the Head of Commercialization at , a wearable neurostimulator sleeve for those with neuromuscular disease ***This podcast is sponsored by Iris Biomedical, check out their Neurotech Startup Services Top 3 Takeaways: "There isn't any individualized training that needs to happen. What needs to happen is the identification of which muscle groups need support and have those turned on and programmed in intensity appropriately." "We were able to improve door sub selection and inversion in more than 90% of our participants." "There's nothing like getting an appreciation for a problem like the...
info_outlinePaul Meadows is one of the founding members of IFESS and a veteran in the neurotech industry. He is currently the Chief Technology Officer at Imthera in the development of neurostimulation device for obstructive sleep apnea. The company was recently acquired by LivaNova. Previous Meadows was involved with neurotech development at Advanced Bionics as well as the Alfred E. Mann Foundation.
Takeaways:
1. Current technology transfer developments are influenced by peer-reviewed published research.
2. Learn from the past so we don’t repeat in the future, applies to neurotech applications.
3. We still have technology challenges in such areas as cybersecurity and battery technology as well as systemic in clinical technology adoption.
[0:00] Ladan introduces the episode and joins the conversation with Paul Meadows and Jen French.
[1:02] Paul Meadows describes his involvement and various positions with IFESS since the inception of the organization.
[1:46] Discussion of his view of the evolution of IFESS over the years.
[2:35] Meadows describes the importance of peer-reviewed publications and the need to
review past research.
[3:43] There are obstacles for technology adoption such as clinical physical therapist curriculum.
[3:58] Meadow’s outlook for exciting developments in the next 5 years in miniaturization, packaging and user-friendly interfaces. This is accompanied by identified risks such as cybersecurity.
[5:52] Identifying that there is some basic science that is limiting technology advancements such as battery technology.